| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 101.9 | 82.1 |
| Profit before tax | -23.2 | 7.8 |
| Net income | -23.2 | 8.0 |
| EPS (diluted, $ a share) | $-0.07 | $0.03 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +24.0% |
|---|---|
| Operating margin | -2.1% |
10-Q filed with the SEC, NASDAQ: MNKD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Mannkind Corp: key numbers
- Share price
- $3.95Close, Nov 16
- Market cap
- $1.27B
- Shares outstanding
- 321.64MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Mannkind Corp
All →Mannkind Financial Results
MannKind Corporation reported third quarter 2026 total revenues of $101.9 million, a 24% increase year-over-year, driven by the commercial launch of Furoscix ReadyFlow and strong pediatric uptake for Afrezza. The company also highlighted positive Phase 1b results for its nintedanib DPI program and a new licensing collaboration with Rose Pharma for an inhaled GLP-1.
“The third quarter marked an important transition for MannKind as we shifted from delivering on three major catalysts to executing against them. We are focused on scaling two commercial launches while supporting three programs in IPF. Furoscix ReadyFlow is off to an exceptionally strong start, and we believe Furoscix will generate more revenue in the fourth quarter than it did in the first half of 2026. ReadyFlow significantly expands the opportunity ahead and reinforces our conviction that Furoscix can be transformational for MannKind and the patients we serve.”
Michael Castagna, Chief Executive Officer of MannKind